FIGURE 6.5. In vivo retrograde transfection of cationized gelatin-plasmid DNA polyplex.

FIGURE 6.5

In vivo retrograde transfection of cationized gelatin-plasmid DNA polyplex. A: Representative L4 DRG sections 60 hours after unilateral injection of CG/pSilencer1.0U6-GAPDH polyplexes and fast blue (FB) injection. Left panels show sections immu-nolabeled for GAPDH (green); FB+ cells appear blue. Right panels show identical sections without FB overlay. FIGURE 6.5. In vivo retrograde transfection of cationized gelatin-plasmid DNA polyplex. : FB+ cells showing GAPDH suppression. B, C: GAPDH immunoreactivity in individual FB+ cells of L4 DRG ipsilateral (B: n = 126 cells) and contralateral (C: n = 139 cells) to CG/pSilencer1.0U6-GAPDH injection. The data show a significant downward shift in GAPDH labeling intensity in ipsilateral FB+ cells after CG/pSilencer1.0U6-GAPDH injection (p = 0.028). (A-C are adapted from Thakor et al. 2007.) D: Acutely dissociated L4/L5 DRG neurons after injection of CG/NaV1.8 siRNA-GFP plasmid DNA polyplexes or CG/p11 competitor-GFP plasmid DNA polyplexes. (A, B, and C: Reprinted with permission from Thakor et al., 2007 Molecular Therapy, 15(12): 2124–31.)

From: Chapter 6, Molecular Strategies for Therapeutic Targeting of Primary Sensory Neurons in Chronic Pain Syndromes

Cover of Translational Pain Research
Translational Pain Research: From Mouse to Man.
Kruger L, Light AR, editors.
Boca Raton, FL: CRC Press; 2010.
Copyright © 2010 by Taylor and Francis Group, LLC.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.